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 Carbonyl reductase 1 catalyzes 20β-reduction of glucocorticoids, 1 
modulating receptor activation and metabolic complications of obesity 2 
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 Supplementary Materials: 39 
SM1 Quantification of urinary glucocorticoid metabolites 40 
Glucocorticoids were extracted from equine urine (20mL) by solid phase extraction on Bond 41 
Elut Nexus mixed mode Large Reservoir Capacity, 60 mg columns (Agilent Technologies, 42 
Santa Clara, CA, USA). Glucocorticoids were extracted from human urine (10mL) by solid 43 
phase extraction on Sep-Pak columns (Waters, Milford, MA, USA).  44 
Steroid conjugates were hydrolysed using β-glucuronidase followed by re-extraction. The 45 
steroids obtained were derivatized to form methoxime-trimethylsilyl (MO-TMS) derivatives. 46 
Steroidal derivatives were separated by gas chromatography using the TRACE GC Ultra Gas 47 
Chromatograph (Thermo Fisher Scientific). Analysis was performed on a TSQ Quantum Triple 48 
Quadrupole GC-tandem mass spectrometer (Thermo Fisher Scientific) using a 35HT 49 
Phenonemex column (30m, 0.25mm, 0.25µm, Agilent Technologies) as previously described 50 
(45, 46). Epi-cortisol and epi-tetrahydrocortisol were used as internal standards (Steraloids, 51 
Newport, RI, USA). The steroids analyzed were cortisol (F), cortisone (E), 5β-52 
tetrahydrocortisol (5β-THF), 5β-tetrahydrocortisone (5β-THE), 5α-tetrahydrocortisol (5α-53 
THF) (45, 46) with the inclusion of the following transitions (collision energy)  α-cortol 54 
(535→355, 20V) and β-cortol (535→455, 10V), α- and β-cortolone (449→269, 10V), 6β-55 
hydroxycortisol (693→513, 10V), 20α- dihydrocortisol (578→488, 10V) and 20β-56 
dihydrocortisol (681→578, 10V). 57 
 58 
Steroid quantities in equine urine were expressed as a ratio to creatinine, which was measured 59 
using a colorimetric method based on the modified Jaffe’s reaction (IL650 analyser, 60 
Instrumentation Laboratories, Barcelona, Spain). 61 
SM2 Quantification of glucocorticoids in plasma 62 
 Plasma samples (1 mL Equine, 200 μL Human) enriched with internal standard (D4-F, D4-E 63 
and D8-B; 250 ng of each) were extracted by liquid-liquid extraction. Chloroform (10 volumes) 64 
was added to each sample, mixed and the organic layer was dried under nitrogen (60 °C). The 65 
extracts were re-suspended in mobile phase (60 µL, water: methanol 70:30 v/v) for 66 
quantification of steroids by LC-MS/MS. The injection volume was 30 µL.  67 
SM3 Quantification of glucocorticoids in adipose tissue 68 
Adipose samples (100mg) were homogenized in ethyl acetate (1 mL) and enriched with internal 69 
standard (D4-F, D8-E, D8-B; 250ng of each). The homogenate was slowly dripped onto chilled 70 
ethanol: glacial acetic acid: water (95:3:2 v/v, 10 mL) and frozen at -80 °C overnight. Samples 71 
were thawed (4 °C) prior to sonication (8 x 15 second bursts) and centrifugation (3000 x g, 30 72 
mins, 4 °C). The supernatant was dried under nitrogen (60 °C), re-suspended in methanol (10 73 
mL) and frozen at -80 °C overnight. Samples were thawed (RT) and hexane (10 mL) added 74 
and mixed. The hexane layer was removed, the remaining methanol dried down under nitrogen 75 
(60 °C) and re-suspended in water (400 µL) and ethyl acetate (4 mL). The organic layer was 76 
removed, dried under nitrogen (60 °C) and re-suspended in 30 % methanol (5 mL). C18 Bond 77 
Elut columns (Agilent Technologies, Santa Clara, CA, USA) were conditioned (methanol 5 78 
mL) and equilibrated (water 5 mL), samples were loaded and steroids eluted with methanol (2 79 
mL). Eluates were dried down under nitrogen (60 °C) and re-suspended in 60 µL mobile phase 80 
(water: methanol, 70:30 v/v) for quantification of steroids by LC-MS/MS. Injection volume 81 
was 30 µL.  82 
SM4 Quantification of mRNA by RT-qPCR 83 
Total RNA was extracted from adipose and liver using the RNAeasy Mini Kit (Qiagen Inc, 84 
Valencia, CA, USA). The tissue was mechanically disrupted in either QIAzol (Qiagen) for 85 
 adipose tissue or RLT buffer (Qiagen) for liver tissue. Total RNA was extracted from cells in 86 
QIAzol lysis reagent using an RNeasy Mini Kit according to the manufacturer’s instructions. 87 
Quantitative real-time polymerase chain reaction was performed using a Light-cycler 480 88 
(Roche Applied Science, Indianapolis, IN, USA). Primers were designed using sequences from 89 
the National Centre of Biotechnological Information and the Roche Universal Probe Library 90 
(see Table S7-9) for details of primers for genes of interest and housekeeping genes). Samples 91 
were analysed in triplicate and amplification curves plotted (y axis fluorescence, x axis cycle 92 
number). Triplicates were deemed acceptable if the standard deviation of the crossing point 93 
was < 0.5 cycles. A standard curve (y axis crossing point, x axis log concentration) for each 94 
gene was generated by serial dilution of cDNA pooled from different samples and fitted with 95 
a straight line and deemed acceptable if reaction efficiency was between 1.7 and 2.1. 96 
  
Supplementary Tables and Figures 
Table S 1 Characteristics of equine study subjects  
 Lean (n=14) Obese (n=14) 
Age (years) 
 
15.6 ± 5.6 13.8 ± 7.8 
Sex 4 Females 
10 Castrated males 
8 Female 
5 Castrated males 
Breeds 11 Thoroughbred  
2 Native pony 
1 Percheron 
2 Thoroughbred 
3 Cob 
7 Native ponies 
1 Arab pony 
1 Clydesdale 
Body condition score 
(/5)  
 
2.3 ±  0.3 3.8 ± 0.7* 
Data are expressed as mean ± SEM. Student’s t-test or Mann-Whitney U test: *p<0.05 
  
Table S 2 Characteristics of obese human participants with type 2 diabetes providing 24 hour 
urine samples 
 
n 19 
Age (years) 58.9 ± 1.5 
Body Mass Index 
(kg/m2) 
32.60 ± 1.2 
Concurrent 
medications 
4 no medication 
15 metformin 
All participants were male and diagnosed with diabetes. Participants provided 24 hour urine 
samples. The additional lean and obese participants providing urine were recruited as part of 
a different study (Upreti et al 2014). Data are expressed as mean ± SEM. 
 Table S 3 Characteristics of lean and obese study participants providing plasma samples 
 Lean (n=10) Obese (n=10) 
Age (years) 50.5 ± 10.4 50.0 ± 11.8 
Body Mass Index 
(kg/m2) 
23.8 ± 1.2 32.9 ± 2.7 
Concurrent 
mediciations 
 6 No medication 
 1 perindopril, 
nifedipine, 
 1 citalopram, 
simvastatin, 
clopidogrel, ranitidine 
 1 clomipramine 
 1 ranitidine 
 8 No medication 
 1 tamsulosin, lansoprazole 
 1 pantoprazole 
Plasma was collected (between 8 and 9am) from lean and obese but otherwise healthy men. 
Participants with diabetes or prior corticosteroid treatment were excluded prior to 
recruitment. Data are expressed as mean ± SEM. 
 
Table S 4 Characteristics of lean and obese men providing adipose biopsy samples during 
surgery. 
 Lean (n=8) Obese (n=8) 
Age (years) 55.7 ± 12.7 52.8 ± 13.7 
Body Mass Index 
(kg/m2) 
23.0 ± 1.7 38.8 ± 6.7 
Surgery  Cholecystectomy 
 Laparoscopic 
cholecystectomy 
 Removal of gastric 
band 
 Hernia repair 
 Open cholecystectomy 
 3 Abdominal hernia 
repairs 
 Gastric bypass 
 Laparoscopic sleeve 
gastrectomy 
 Laparoscopic cholecystectomy 
 Cholecystectomy 
 2 Laparoscopic fundoplications 
 Laparoscopic cholecystectomy 
 Laparoscopic removal of 
gastric band and gastric bypass 
All the participants were male. Samples were obtained at the time of surgery. Data are 
expressed as mean ± SEM.
 Table S 5 Estimates of the phenotypic associations with CBR1 expression in the liver 
based on Mendelian Randomisation 
 
Outcome Beta Se P value N Sample 
BMI -0.01 0.01 0.25 339224 (55) 
Body Fat -0.01 0.01 0.06 100716 (56) 
2hr glucose 
adjusted for BMI 
<0.01 0.03 0.89 15234 (57) 
Fasting glucose 0.01 <0.01 0.02 58074 (58) 
Fasting insulin <0.01 <0.01 0.45 51750 (58) 
HOMA-B <0.01 <0.01 0.59 46186 (59) 
HOMA-IR 0.01 0.01 0.27 46186 (59) 
HbA1c 0.01 <0.01 0.01 46368 (60) 
These analyses used rs1005696 as the instrument for CBR1 expression in liver and 
associations were analysed using MR-base. See supplementary references for further 
details of studies used.  
 
 
 Table S 6 Human primer sequences for PCR 
 
 
Table S 7 Equine primer sequences for PCR 
Gene Symbol, 
full name 
Forward Primer (3’→ 5’) Reverse Primer (5’→ 3’) 
RNA18s  
(ribosomal RNA 
18s) 
CTTCCACAGGAGGCCTACA
C 
CGCAAAATATGCTGGAACT
TT 
DUSP1 (dual 
specificity 
phosphatase 1) 
TTCAAGAGGCCATTGACTT CCTGGCAGTGGACAAACA
C 
GILZ 
(glucocorticoid- 
induced leucine 
zipper) 
CCGTTAAGCTGGACAACAG
TG 
ATGGCCTGTTCGATCTTGT
T 
FKBP51 
(FK506-binding 
protein 51) 
GGATATACGCCAACATGTT
CAA 
CCATTGCTTTATTGGCCTCT 
IGFBP1 
(insulin-like 
growth factor 
binding protein 
1) 
GCCTTGGCTAAACTCTCTA
CGA 
CCATGTCACCAACATCAAA
AA 
IL-1β 
(Interleukin 1β) 
TGTAATGAAAGACGGCACA
CC 
TCTTCTTTGGGTATTGCTTG
G 
CBR1 
(Carbonyl 
Reductase 1) 
TCCCTCTAATAAAACCCCA
AGG 
GGTCTCACTGCGGAACTTC
T 
Gene Symbol, 
full name 
Forward Primer (3’→ 5’) Reverse Primer (5’→ 3’) 
RNA18s 
(ribosomal RNA 
18s) 
TGACCCAAGGCTAGTAGCT
GA 
TTCAACACATCACCCACCA
T 
SDHA 
(Succinate 
CTACGGAGACCTTAAGCAT
CTGA 
GGGTCTCCACCAGGTCAGT
A 
  
 
Table S 8 Murine primer sequences for PCR 
dehydrogenase 
complex) 
Equine CBR1 
(Carbonyl 
Reductase 1) 
ACCCAGCCATGTCTTACAC
C 
CAGGATAGTGAAGCCGAT
GC 
Gene Symbol, full 
name 
Forward Primer (3’→ 5’) Reverse Primer (5’→ 3’) 
RNA18s (ribosomal 
RNA 18s)   
CTCAACACGGGAAACCT
CAC 
CGCTCCACCAACTAAGA
ACG 
Tbp (TATA-binding 
protein)  
  
GGGAGAATCATGGACCA
GAA 
GATGGGAATTCCAGGAG
TCA 
Per1 (Period 1) GCTTCGTGGACTTGACAC
CT  
 
TGCTTTAGATCGGCAGT
GGT  
 
Pepck  
(phosphoenolpyruvate 
carboxykinase) 
GAGGCACAGGTCCTTTTC
AG 
GTTCCTGGGCCTTTGTG
AC 
Adipq (Adiponectin) GGTGAGAAGGGTGAGAA
AGGA 
TTTCACCGATGTCTCCCT
TAG 
Lpl (Lipoprotein 
lipase) 
CTCGCTCTCAGATGCCCT
AC  
 
GGTTGTGTTGCTTGCCAT
T  
 
Sgk1 (serum 
glucocorticoid kinase 
1) 
TTTCCAAAGGGGGATGC
T 
TGTTGGCATGATTACAT
TGTTCT 
ENaC1 (Epithelial 
sodium channel 1) 
AGCACAGAGAACACCCC
TGT 
TGGCTCTTCCTACCCTCT
CTC 
Cbr1 
(Carbonyl Reductase 
1) 
AGGTGACAATGAAAACG
AACTTT 
GGACACATTCACCACTC
TGC 
 Figure S 1 The human urinary glucocorticoid metabolite profile in lean and obese individuals 
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Urinary glucocorticoids of lean and obese participants were extracted, derivitized and 
quantified by GC-MS/MS. Urinary excretion of 20β-dihydrcortisol was higher in the obese 
group. 
 
Figure S 2 Equine liver cytosol metabolises cortisol to 20β-dihydrocortisol and this 
production is inhibited by quercetin 
  
 
 
  
 
[A] In the presence of NADPH equine liver cytosol produced 20β-DHF as the predominant 
metabolite. (THF = tetrahydrocortisol, THE = tetrahydrocortisone). [B] CBR1 inhibitor 
quercetin prevented production of 20β-DHF by equine liver cytosol. Data are mean ± SEM. 
 
Figure S 3 20β-Dihydrocorticosterone is present in murine tissues 
 
 
 
 
20β-Dihydrocortisone (the murine equivalent of 20β-dihydrocortisol) was measured by LC-
MS/MS in murine [A] plasma and [B] liver. Data are mean ± SEM. 
 Figure S 4 20β-Dihydrocorticosterone induces murine glucocorticoid receptor activation  
 
HEK293 cells transfected with murine GR-MMTV-Luc were incubated with increasing 
concentrations of 20β-dihydrocorticosterone (20β-DHB) the murine equivalent of 20β-
dihydrocortisol. Data are mean ± SEM, *P<0.05 compared to vehicle. 
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